Photo taken from Erman Akkus/X
May 28, 2024, 07:11
SENECA study summarized by Erman Akkus
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:
“FOLFIRI vs. CapTem in the second line after platinum/etoposid for NECs
SENECA study
The two regimens showed comparable activity
- GEP and lung NECs
- 12 weeks-Disease Control Rate 39.1% vs 28%
- 12 mo OS 28.4% vs 32.4%
- FOLFIRI: neutropenia, anemia
- CapTem: thrombocytopenia, nausea/vomiting
The study was halted for futility as the minimum 12w-DCR threshold of 10 out of 25 patients was not reached.”
Source: Erman Akkus/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19